Boston Life Sciences Names Kenneth L. Rice Jr. as Chief Financial Officer.BOSTON -- Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) today announced that Kenneth L. Rice, Jr., JD, LLM LLM abbr. Latin Legum Magister (Master of Laws) LLM Master of Laws [Latin Legum Magister] Noun 1. , MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration has been appointed Executive Vice President of Finance & Administration, Chief Financial Officer and In-House Counsel effective July 1, 2005. Peter Savas, BLSI's Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented, "I am pleased that Ken has joined BLSI's executive management team. Ken's relationships in the life sciences market coupled with his expertise in finance, commercial development, corporate governance Corporate Governance The relationship between all the stakeholders in a company. This includes the shareholders, directors, and management of a company, as defined by the corporate charter, bylaws, formal policy, and rule of law. and business law will help us achieve our business plan." Savas went on to say, "We thank Joe Hernon for his contributions to BLSI throughout the last eight years. Joe's financial and administrative efforts played an important role in BLSI's early development. For the past nine months he has worked diligently with me to successfully restructure the capitalization of the Company. We appreciate his continued assistance in the near term to ensure a smooth transition." Mr. Rice brings over 25 years of experience in life sciences related businesses. Most recently, Mr. Rice served as V.P., Chief Financial Officer and Chief Commercial Officer of Aderis Pharmaceuticals, a privately-held biopharmaceutical company. Mr. Rice previously held executive positions with MacroChem Corporation, Pentose pentose /pen·tose/ (pen´tos) a monosaccharide containing five carbon atoms in a molecule. pen·tose n. Pharmaceuticals, Unisyn Technologies, Zymark Corporation and Millipore Corporation. Mr. Rice earned his LLM Taxation from Boston University Law School, his Juris Doctor Cum Laude from Suffolk University Law School The law school currently has both day and evening (part-time) divisions. The school is located in the newly built Sargent Hall on Tremont Street in downtown Boston. There are over 200 upper level electives offered at the law school, and the school is consistently ranked one of the most and his MBA and BS/BA from Babson College. Boston Life Sciences, Inc. (BLSI) is a biotechnology company primarily focused in the research and clinical development of biopharmaceutical products for the diagnosis and treatment of central nervous system, or CNS See Continuous net settlement. CNS See continuous net settlement (CNS). , diseases. Statements in this press release regarding management's future expectations, beliefs, goals, plans or prospects may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in the Company's Quarterly Report on 10-Q for the quarter ended March 31, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, the Company's actual results may differ materially from the results discussed in or implied by the forward-looking statements contained herein. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will" and "would" or similar words. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Our logo, trademarks, and service marks are the property of Boston Life Sciences, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Boston Life Sciences, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion